Overactive bladder mirrors more than $2 Billion annual market opportunity in the U.S..
The Product
Vensica is developing a unique solution to urology, using a proprietary premium botulinum toxin A and a needle-free delivery device.
The Team
Read about the people behind the companyy. The respected leaders of therapeutics in urology.
What Professionals Say
Vensica could change the way we manage OAB
Prof. Alan Wein (hon) Founder Professor and Chief of urology at the University of Pennsylvania. A pioneer in the overactive bladder space
Vensica can be a home run and a victory
Prof. Roger Dmochowski A key opinion leader urologist from Vanderbilt Uni. Medical Center, Nashville, TN. Allergan’s PI in clinical trials for Botulinum Toxin A for OAB